Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew Loar Insider Profile
4 Followers
Matthew Loar, CFO at Oncotelic Therapeutics, holds 300.00K shares in Oncotelic Therapeutics (Ticker: OTLC), holds 4.56K shares in Paratek Pharmaceuticals (Ticker: PRTK).
Matthew Loar has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CFO
Roles that Matthew Loar holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Matthew Loar
Matthew Loar's Trading History
Oncotelic Therapeutics
Apr 16, 2018
CFO
Uninformative Buy
―
$11.70K
Paratek Pharmaceuticals
Dec 17, 2013
―
Uninformative Buy
―
$10.17K
List of latest transactions for each holding click on a transaction to see Matthew Loar's performance on stock
You May Also Like
Matthew Loar insider profile FAQ
What is the percentage of profitable transactions made by Matthew Loar?
The percentage of profitable transactions made by Matthew Loar is ―.
What is the average return per transaction made by Matthew Loar?
The average return per transaction made by Matthew Loar is ―.
What stocks does Matthew Loar hold?
Matthew Loar holds: OTLC, PRTK stocks.
What was Matthew Loar’s latest transaction?
Matthew Loar latest transaction was an Uninformative Buy of ―.
What was Matthew Loar's most profitable transaction?
Matthew Loar’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Matthew Loar's role in Oncotelic Therapeutics?
Matthew Loar's role in Oncotelic Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.